FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808448539> ?p ?o ?g. }

• W2808448539 endingPage "27928" @default.
• W2808448539 startingPage "27920" @default.
• W2808448539 abstract "// Alessandra Cataldo 1 , Claudia Piovan 1 , Ilaria Plantamura 1 , Elvira D’Ippolito 1 , Simone Camelliti 1 , Patrizia Casalini 2 , Marta Giussani 2 , Olivier Déas 3 , Stefano Cairo 3 , Jean-Gabriel Judde 3 , Elda Tagliabue 2 and Marilena V. Iorio 1 1 Start Up Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy 2 Molecular Targeting Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy 3 Xentech, Genopole Campus 3, Evry, Paris Correspondence to: Marilena V. Iorio, email: marilena.iorio@istitutotumori.mi.it Keywords: microRNA; breast cancer; HER2-3; trastuzumab; biomarkers Abbreviations: BC: breast cancer; TKI: tyrosin kinase inhibitor; PR: pathological response; PDX: patient-derived xenograft Received: December 30, 2017      Accepted: February 25, 2018      Published: June 15, 2018 ABSTRACT Trastuzumab is the standard treatment for HER2+ breast cancer (BC) patients, and even though it significantly improved their clinical outcome, 50% of them do not benefit from this drug and disease recurs, underlining the need of reliable predictive biomarkers and new therapeutic strategies. Strikingly, despite all the molecular analyses performed to identify the escape mechanisms behind this resistance, it still represents a question point. MiRNAs have been correlated with occurrence and progression of human cancer, and their potential as clinical tools has emerged in the last years. We previously reported that oncosuppressive miR-205 targets HER3, thus increasing the responsiveness to TKIs lapatinib and gefitinib in preclinical models. Here we demonstrate that HER3 inhibition by miR-205 ectopic expression or siRNA-mediated silencing improves the responsiveness to Trastuzumab in vitro in HER2+ BC cell lines, and that this effect is exerted through impairment of AKT-mediated pathway. Moreover, evaluating a series of 52 HER2+ BC patients treated with adjuvant Trastuzumab, we observed that higher miR-205 expression is significantly associated with better outcome (disease-free survival). In summary, our data indicate that miR-205 could predict Trastuzumab efficacy and that its modulation might be useful as adjuvant treatment to improve the response to the drug." @default.
• W2808448539 created "2018-06-21" @default.
• W2808448539 creator A5001597492 @default.
• W2808448539 creator A5011020262 @default.
• W2808448539 creator A5013074741 @default.
• W2808448539 creator A5037500005 @default.
• W2808448539 creator A5039898933 @default.
• W2808448539 creator A5058013683 @default.
• W2808448539 creator A5059103000 @default.
• W2808448539 creator A5062667699 @default.
• W2808448539 creator A5064003777 @default.
• W2808448539 creator A5070363091 @default.
• W2808448539 creator A5077046461 @default.
• W2808448539 creator A5083469846 @default.
• W2808448539 date "2018-06-15" @default.
• W2808448539 modified "2023-10-17" @default.
• W2808448539 title "MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab" @default.
• W2808448539 cites W1482814115 @default.
• W2808448539 cites W1771120914 @default.
• W2808448539 cites W1965714535 @default.
• W2808448539 cites W1971209307 @default.
• W2808448539 cites W1973144992 @default.
• W2808448539 cites W1984144828 @default.
• W2808448539 cites W2000023414 @default.
• W2808448539 cites W2000269004 @default.
• W2808448539 cites W2014661332 @default.
• W2808448539 cites W2021654438 @default.
• W2808448539 cites W2051352765 @default.
• W2808448539 cites W2059433308 @default.
• W2808448539 cites W2068326740 @default.
• W2808448539 cites W2077748586 @default.
• W2808448539 cites W2103576580 @default.
• W2808448539 cites W2108940132 @default.
• W2808448539 cites W2113506041 @default.
• W2808448539 cites W2118419063 @default.
• W2808448539 cites W2135836598 @default.
• W2808448539 cites W2143564454 @default.
• W2808448539 cites W2145848169 @default.
• W2808448539 cites W2149189351 @default.
• W2808448539 cites W2165139474 @default.
• W2808448539 cites W2169961966 @default.
• W2808448539 cites W2219978888 @default.
• W2808448539 cites W2408707838 @default.
• W2808448539 cites W2588025094 @default.
• W2808448539 doi "https://doi.org/10.18632/oncotarget.24723" @default.
• W2808448539 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6021348" @default.
• W2808448539 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29963251" @default.
• W2808448539 hasPublicationYear "2018" @default.
• W2808448539 type Work @default.
• W2808448539 sameAs 2808448539 @default.
• W2808448539 citedByCount "13" @default.
• W2808448539 countsByYear W28084485392019 @default.
• W2808448539 countsByYear W28084485392020 @default.
• W2808448539 countsByYear W28084485392021 @default.
• W2808448539 countsByYear W28084485392022 @default.
• W2808448539 countsByYear W28084485392023 @default.
• W2808448539 crossrefType "journal-article" @default.
• W2808448539 hasAuthorship W2808448539A5001597492 @default.
• W2808448539 hasAuthorship W2808448539A5011020262 @default.
• W2808448539 hasAuthorship W2808448539A5013074741 @default.
• W2808448539 hasAuthorship W2808448539A5037500005 @default.
• W2808448539 hasAuthorship W2808448539A5039898933 @default.
• W2808448539 hasAuthorship W2808448539A5058013683 @default.
• W2808448539 hasAuthorship W2808448539A5059103000 @default.
• W2808448539 hasAuthorship W2808448539A5062667699 @default.
• W2808448539 hasAuthorship W2808448539A5064003777 @default.
• W2808448539 hasAuthorship W2808448539A5070363091 @default.
• W2808448539 hasAuthorship W2808448539A5077046461 @default.
• W2808448539 hasAuthorship W2808448539A5083469846 @default.
• W2808448539 hasBestOaLocation W28084485391 @default.
• W2808448539 hasConcept C121608353 @default.
• W2808448539 hasConcept C126322002 @default.
• W2808448539 hasConcept C143998085 @default.
• W2808448539 hasConcept C185592680 @default.
• W2808448539 hasConcept C2777329042 @default.
• W2808448539 hasConcept C2779438470 @default.
• W2808448539 hasConcept C2779786085 @default.
• W2808448539 hasConcept C2780580887 @default.
• W2808448539 hasConcept C2781197716 @default.
• W2808448539 hasConcept C530470458 @default.
• W2808448539 hasConcept C55493867 @default.
• W2808448539 hasConcept C71924100 @default.
• W2808448539 hasConceptScore W2808448539C121608353 @default.
• W2808448539 hasConceptScore W2808448539C126322002 @default.
• W2808448539 hasConceptScore W2808448539C143998085 @default.
• W2808448539 hasConceptScore W2808448539C185592680 @default.
• W2808448539 hasConceptScore W2808448539C2777329042 @default.
• W2808448539 hasConceptScore W2808448539C2779438470 @default.
• W2808448539 hasConceptScore W2808448539C2779786085 @default.
• W2808448539 hasConceptScore W2808448539C2780580887 @default.
• W2808448539 hasConceptScore W2808448539C2781197716 @default.
• W2808448539 hasConceptScore W2808448539C530470458 @default.
• W2808448539 hasConceptScore W2808448539C55493867 @default.
• W2808448539 hasConceptScore W2808448539C71924100 @default.
• W2808448539 hasIssue "46" @default.
• W2808448539 hasLocation W28084485391 @default.
• W2808448539 hasLocation W28084485392 @default.
• W2808448539 hasLocation W28084485393 @default.

• next